Innovative Bio-pharmaceuticalCompany July 2009

2Safe Harbor StatementThis presentation contains forward-looking statements. All statements, other than statements of historical facts, including, among others, statements regarding the Company’s future financial position, business strategy, projected levels of growth, projected costs and projected financing needs, are forward-looking statements. Those statements include statements regarding the intent, belief or current expectations of Rockwell Medical Technologies, Inc. and members of the Company’s management team, as well as the assumptions on which such statements are based, and generally are identified by the use of words such as “may,” “will,“ “seeks,” “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends,” “should” or similar expressions. Forward looking statements are not guarantees of future performance and involve risks and uncertainties that actual results may differ materially from those contemplated by such forward-looking statements.The company believes these forward-looking statements are reasonable; however, undue reliance should not be placed on any forward-looking statements, which are based on current expectations. All written and oral forward-looking statements attributable to the Company or persons acting on its behalf are qualified in their entirety by these cautionary statements. Further, forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time unless required by law.

Agenda3

Corporate Overview4

5Corporate SummaryBio-pharmaceutical drug company with established operating businessDevelopment of unique, proprietary renal drugsLead drug iron delivery via dialysate – new standard of care Expect superior patient outcomes vs. current therapiesWomen’s health, oncology and parenteral nutritionStrong, growing core operating renal businessBroad distribution channel and manufacturing base3 manufacturing plants; 27% U.S. market shareDialysate; removes toxins and replaces nutrients in blood Products needed to maintain human lifeProvided 16.6 million+ treatments in 2008

6Kidney Disease MarketChronic kidney disease (CKD) 19.2 million Progressive loss of renal function; 5-StagesEnd Stage Renal Disease (ESRD) – irreversible loss of kidney function  need dialysis to liveStage 5 = 395,000 US patients; 2 million worldwideStages 3 and 4 = 8.1 million US patientsSteady, growing market unaffected by economiesCausesDiabetes and obesity, CVD, hypertension, agingCurrent treatment optionsDialysis: life-saving blood filtering treatmentKidney transplant

Lead Drug CandidateSFPSoluble Ferric Pyrophosphate7

SFP – Iron via Dialysate8 Dialysis Dialyzer Blood flows through Dialyzer membrane Dialysate flows outside of membrane in opposite directionNutrients (Ca, K, Mg, Na) delivered into blood while toxins and waste are removedSFP (iron) now delivered into blood via dialysate just like nutrientsReplaces kidney functionRemoves waste and excess fluids Replenishes nutrients3-4 hour treatment

Blood flows through Dialyzer membrane

Dialysate flows outside of membrane in opposite direction

Nutrients (Ca, K, Mg, Na) delivered into blood while toxins and waste are removed

SFP (iron) now delivered into blood via dialysate just like nutrients

Replaces kidney function

Removes waste and excess fluids

Replenishes nutrients

3-4 hour treatment

SFP – Iron via DialysateBio-available iron delivered directly to blood streamReplaces iron in blood lost during each dialysis treatmentRapid uptake of iron by transferrinTransferrin takes iron to bone marrowMaintains iron balance within target hemoglobin rangeInside Dialyzer Filter9

Bio-available iron delivered directly to blood stream

Replaces iron in blood lost during each dialysis treatment

Rapid uptake of iron by transferrin

Transferrin takes iron to bone marrow

Maintains iron balance within target hemoglobin range

10SFP AdvantagesPhysiological iron maintenance therapySlow infusion (10-15 µg/dL iron dose) via dialysate during scheduled dialysis session; 3X per week; works like dietary ironSmall dose replaces 5-7mg avg blood loss per sessionMaintains iron balance  efficiently matches EPO and hemoglobinSuperior safety benefits for patient + lowers provider costSafely travels direct to bloodstream  bypasses liver and avoids toxicity~2000 Clinical Doses to Date  No Adverse ReactionsSignificantly lowers IV iron administration costs eliminates needles, syringes and RN time Bundled reimbursement provides superior patient-outcome at lowest cost; significant EPO savings expected Market potentialU.S. IV iron CKD $500 million ($430M+ ESRD)Global IV iron CKD $850 millionU.S. dialysis concentrates $180 million

Maximizes ErythropoiesisBy maintaining constant iron balance SFP maximizes creation of red blood cells, generation of hemoglobin and optimization of EPO treatment response11

SFP vs IV IronHemodialysis Dependent Chronic kidney Disease (HDD-CKD)12* high molecular weight sugar molecules have been linked to anaphylactic reactions; not present in SFP

SFP Development Program13

SFP Phase IIb StudyPrimary Endpoint: Drop in hemoglobin of 1 gm/dL or more and safety.Secondary Endpoints: Time taken to drop hemoglobin by 1 g/dL or more, increase in hemoglobin to more than 12.5 g/dL, reticulocyte hemoglobin, infection, iron transferred into the patient.Enrollment completed April 2009Two positive Data Safety Monitoring Board (DSMB) reviews to date; validates SFP superior safety profileExpect data Q4 2009 / Q1 201014

SFP Commercial Launch: 2012 15Strategy: Leverage captive client relationships and distribution channels for fast SFP penetration* Forecast

Intellectual PropertyRockwell owns exclusive worldwide licensePatents issued in U.S, Europe and Japan  three largest ESRD markets in the worldIron delivery via dialysate in hemodialysis (HD) and peritoneal dialysis (PD)Composition of matter and method of delivery Patent expires 2021 (including 5 year Hatch-Waxman)Patent filed on SFP-GMP grade formulationTo cover dialysis, oral OTC/Rx, TPN, Oncology, and other extensions16

Financial Overview17

Key Financial Facts18*As of July 24, 2009**As of 1Q09**Excluding cash flow generation from core business

Annual Sales Growth 19($, in Millions)2008Forecast*5-Year CAGR 23.6%

Investment Opportunity & Upcoming Milestones20

Investment OpportunityBio-Pharma transitionInnovative, proprietary disruptive technology with lead-drug candidate SFP Safer, more effective and substantial cost savingsSignificant market potential $500M U.S. / $850M GlobalReady-made commercial distribution channel for fast market penetration of high-margin renal drugsSolid customer base; $51.6M revenues in 2008 Captive 35% market share to leverage ($88M) in 2011*Regulatory development progressing Ongoing Phase IIb FDA study / NIH funded studyPhase III study anticipated to begin enrollment Q2 2010FDA approval and commercial launch anticipated 2011/2012*Forecast21

Investment OpportunityBio-Pharma transitionStrong scientific clinical team; focus SFP success; leverage renal drug pipelineExpanded SAB with 3 new anemia/iron deficiency expertsHired VP of Drug Development and Medical AffairsHired Chief Scientific OfficerSFP formulation opportunity – leveraging into new markets Secured other proprietary renal drugsFavorable environment for bio-pharma therapeutics – big pharma pipelines scarce Opportunistic market conditionsGrowing, worldwide renal patient population unaffected by economic cycles; predictable recurring revenuesCritical need for iron therapeutics and renal products CMS bundling 2011 – should prove favorable to SFP and extension opportunities22

Upcoming Milestones23

Innovative Bio-pharmaceuticalCompany30142 Wixom RoadWixom, MI 48393 USA(248) 960-9009invest@rockwellmed.com

Appendix

FDA Clinical Studies26

EPO & Hemoglobin GenerationIt takes 25 days to create a red blood cell- Day 16: EPO receptors surround, protect, and incorporate into cell in order for it to mature- Day 19-20: more transferrin receptors exist around cell looking for iron to incorporate into cell It is crucial that iron be present between day 19-20 (not effective to add it later)  important to maintain iron balance all the time - Day 21: If iron exists to incorporate into cell, it becomes a reticulocyte  iron used to generate hemoglobin reticulocyte  mature red blood cell (RBC) within 4 days27